AC
AMLX icon

AXQ Capital’s Amylyx Pharmaceuticals AMLX Stock Holding History

AXQ Capital’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-10,836
Closed -$198K – 636
2023
Q3 		$198K Buy
+10,836
New +$229K 0.07% 392
2023
Q2 		– Sell
-10,600
Closed -$311K – 282
2023
Q1 		$311K Buy
+10,600
New +$368K 0.12% 293

Other funds holding AMLX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AXQ Capital's AMLX Position: Q4 2023 in Review

AXQ Capital sold out of Amylyx Pharmaceuticals (AMLX) in Q4 2023, closing a stake of 10,836 shares — an estimated $198K sold.

AXQ Capital first reported a position in AMLX in Q1 2023 and held it in 2 quarters. The position peaked at $311K in Q1 2023. 178 funds tracked by Wall St. Rank hold AMLX as of Q4 2023.

  • AXQ Capital reported no remaining Amylyx Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • AXQ Capital sold 10,836 Amylyx Pharmaceuticals shares in Q4 2023, an estimated $198K.
  • AXQ Capital first reported a position in Amylyx Pharmaceuticals in Q1 2023 and held it in 2 quarters.
  • AXQ Capital's Amylyx Pharmaceuticals position peaked at $311K in Q1 2023.
  • 178 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q4 2023.

Based on AXQ Capital's 13F filing for Q4 2023, filed 13 Feb 2024.